SNPase-ARMS qPCR: Ultrasensitive mutation-based detection of cell-free tumor DNA in melanoma patients

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Stadler, Julia ^a,b   Eder, Johanna ^c,d   Pratscher, Barbara ^b   Brandt, Sabine ^b   Schneller, Doris ^a,b,e   Müllegger, Robert ^a   Vogl, Claus ^b   Trautinger, Franz ^c,d   Brem, Gottfried ^a,b   Burgstaller, Joerg P ^a,b  

^a IFATulln ^*  (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c Universitätsklinikum Tulln Karl Landsteiner Privatuniversität für Gesundheitswissenschaften   (Austria)

^d Karl Landsteiner Institute of Dermatological Research   (Austria)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA POLYMERASE; EXONUCLEASE; B RAF KINASE; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN;

ALLELE; ARTICLE; BLOOD ANALYSIS; BRAF GENE; CELL FREE SYSTEM; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA DETERMINATION; ENZYME ACTIVITY; GENE; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN CELL; METASTATIC MELANOMA; NRAS GENE; POINT MUTATION; POLYMERASE CHAIN REACTION; PTEN GENE; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; BLOOD; CANCER STAGING; COPY NUMBER VARIATION; DNA MUTATIONAL ANALYSIS; GENETICS; MELANOMA; MUTATION; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; TUMOR CELL LINE;

CELL LINE, TUMOR; COHORT STUDIES; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GTP PHOSPHOHYDROLASES; HUMANS; MELANOMA; MEMBRANE PROTEINS; MUTATION; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS;

EID: 84955452903     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142273     Document Type: Article

References (61)

1. Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker - a critical appraisal of the literature. Clin Chim Acta. 2010; 411(21-22):1611-24. Epub 2010/08/07. doi:10.1016/j.cca.2010.07.032 PMID: 20688053.
2. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. doi:10.1038/nrc3066 PMID: 21562580.
3. Siravegna G, Bardelli A. Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol. 2014; 15(8):449. doi:10.1186/s13059-014-0449-4 PMID: 25222559; PubMed Central PMCID: PMC4281953.
4. Haber DA, Velculescu VE Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014; 4(6):650-61. doi:10.1158/2159-8290.CD-13-1014 PMID: 24801577; PubMed Central PMCID: PMC4433544.
5. Diaz LA J.r., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32 (6):579-86. doi:10.1200/JCO.2012.45.2011 PMID: 24449238.
6. Bettegowda C, Sausen M, Leary R.J., Kinde I., Wang Y, Agrawal N, et al Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. doi:10.1126/scitranslmed.3007094 PMID: 24553385; PubMed Central PMCID: PMC4017867.
7. Jones S, Chen WD, Parmigiani G, Diehl F., Beerenwinkel N, Antal T, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA. 2008; 105(11):4283-8. doi:10.1073/pnas.0712345105 PMID: 18337506; PubMed Central PMCID: PMC2393770.
8. Coller HA, Khrapko K, Bodyak N.D., Nekhaeva E., Herrero-Jimenez P, Thilly WG. High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without selection. Nat Genet. 2001; 28(2):147-50. doi:10.1038/88859 PMID: 11381261.
9. Stratton MR, Campbell PJ, Futreal PA The cancer genome. Nature. 2009; 458(7239):719-24. doi:10.1038/nature07943 PMID: 19360079; PubMed Central PMCID: PMC2821689.
10. Pleasance ED, Cheetham RK, Stephens P.J., McBride DJ, Humphray SJ, Greenman CD, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010; 463 (7278):191-6. doi:10.1038/nature08658 PMID: 20016485; PubMed Central PMCID: PMC3145108.
11. Diehl F, Schmidt K, Choti M.A., Romans K., Goodman S, Li M, et al Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008; 14(9):985-90. Epub 2008/08/02. doi: nm.1789 [pii] doi: 10.1038/nm.1789 PMID: 18670422.
12. Wood LD, Parsons DW, Jones S, Lin J., Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318(5853):1108-13. Epub 2007/10/13. doi:1145720 [pii] doi: 10.1126/science.1145720 PMID: 17932254.
13. Benesova L, Belsanova B, Suchanek S, Kopeckova M, Minarikova P, Lipska L, et al. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem. 2013; 433(2):227-34. doi:10.1016/j.ab.2012.06.018 PMID: 22750103.
14. Taly V, Pekin D, Benhaim L., Kotsopoulos SK, LeCorre D, Li X, et al Multiplex picodropletdigital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem. 2013; 59(12):1722-31. doi:10.1373/clinchem.2013.206359 PMID: 23938455.
15. Bidard FC, Weigelt B, Reis-Filho JS. Going with the flow: from circulating tumor cells to DNA. Sci Transl Med. 2013; 5(207):207ps14. doi:10.1126/scitranslmed.3006305 PMID: 24132635.
16. Sanmamed MF, Fernandez-Landazuri S, Rodriguez C, Zarate R, Lozano MD, Zubiri L, et al. Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors. Clin Chem. 2015; 61(1):297-304. Epub 2014/11/21. doi:10.1373/clinchem.2014.230235clinchem.2014. 230235 [pii]. PMID: 25411185.
17. Abdel-Wahab O., Klimek VM, Gaskell AA, Viale A, Cheng D, Kim E, et al. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. Cancer Discov. 2014; 4(5):538-45. doi:10.1158/2159-8290.CD-13-1038 PMID: 24589925.
18. Yancovitz M, Yoon J, Mikhail M, Gai W, Shapiro RL, Berman RS, et al. Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn. 2007; 9(2):178-83. doi:10.2353/jmoldx.2007.060135 PMID: 17384209; PubMed Central PMCID: PMC1867452.
19. Board RE, Ellison G, Orr MC, Kemsley KR, McWalter G, Blockley LY, et al. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer. 2009; 101(10):1724-30. Epub 2009/10/29. PMID: 19861964; PubMed Central PMCID: PMC2778539.
20. Salvianti F, Pinzani P, Verderio P., Ciniselli CM, Massi D, De Giorgi V, et al. Multiparametric analysis of cell-free DNA in melanoma patients. PLoSOne. 2012; 7(11):e49843. doi:10.1371/journal.pone.0049843 PMID: 23209607; PubMed Central PMCID: PMC3507877.
21. Pinzani P, Santucci C, Mancini I., Simi L, Salvianti F, Pratesi N., et al. BRAFV600E detection in melanoma is highly improved by COLD-PCR. ClinicaChimicaActa. 2011; 412(11-12):901-5. doi:10.1016/j.cca.2011.01.014
22. Pinzani P, Salvianti F, Cascella R., Massi D, De Giorgi V, Pazzagli M, et al Allele specificTaqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients. Clin Chim Acta. 2010; 411(17-18):1319-24. Epub 2010/06/26. doi:S0009-8981(10)00354-2 [pii] doi: 10.1016/j.cca.2010.05.024 PMID: 20576522.
23. Shinozaki M, O'Day SJ, Kitago M, Amersi F, Kuo C, Kim J, et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res. 2007; 13 (7):2068-74. Epub 2007/04/04. doi:13/7/2068 [pii] doi: 10.1158/1078-0432.CCR-06-2120 PMID: 17404088; PubMed Central PMCID: PMC2720029.
24. Diehl F, Li M, Dressman D., He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA. 2005; 102(45):16368-73. doi:10.1073/pnas.0507904102 PMID: 16258065; PubMed Central PMCID: PMC1283450.
25. Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F., et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014; 20(4):430-5. doi:10.1038/nm.3511 PMID: 24658074.
26. Mouliere F, El Messaoudi S, Gongora C, Guedj AS, Robert B, Del Rio M, et al. Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. Transl Oncol. 2013; 6(3):319-28. Epub 2013/06/05. PMID: 23730412; PubMed Central PMCID: PMC3660801.
27. Chen D, Huang JF, Xia H, Duan G.J., Chuai ZR, Yang Z, et al. High-sensitivity PCR method for detecting BRAF V600E mutations in metastatic colorectal cancer using LNA/DNA chimeras to block wild-type alleles. Anal Bioanal Chem. 2014; 406(9-10):2477-87. doi:10.1007/s00216-014-7618-x PMID: 24500755.
28. Newman AM, Bratman SV, To J, Wynne J.F., Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014; 20(5):548-54. doi:10.1038/nm.3519 PMID: 24705333; PubMed Central PMCID: PMC4016134.
29. Oxnard GR, Paweletz CP, Kuang Y, Mach S.L., O'Connell A, Messineo MM, et al Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014; 20(6):1698-705. doi:10.1158/1078-0432.CCR-13-2482 PMID: 24429876; PubMed Central PMCID: PMC3959249.
30. Taniguchi K, Uchida J, Nishino K., Kumagai T, Okuyama T, Okami J, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res. 2011; 17(24):7808-15. Epub 2011/10/07. doi:10.1158/1078-0432.CCR-11-17121078-0432. CCR-11-1712 [pii]. PMID: 21976538.
31. Guha M, Castellanos-Rizaldos E, Makrigiorgos GM. DISSECT Method Using PNA-LNA Clamp Improves Detection of T790m Mutation. PLoS ONE. 2013; 8(6):e67782. Epub 2013/06/28. PMID: 23805327; PubMed Central PMCID: PMC3689726.
32. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N EnglJ Med. 2013; 368(13):1199-209. Epub 2013/03/15. doi:10.1056/NEJMoa1213261 PMID: 23484797.
33. Beaver JA, Jelovac D, Balukrishna S, Cochran RL, Croessmann S, Zabransky DJ, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res. 2014; 20(10):2643-50. Epub 2014/02/08. doi:10.1158/1078-0432.CCR-13-29331078-0432. CCR-13-2933 [pii]. PMID: 24504125; PubMed Central PMCID: PMC4024333.
34. Higgins MJ, Jelovac D, Barnathan E., Blair B, Slater S, Powers P., et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res. 2012; 18(12):3462-9. Epub 2012/03/17. doi:10.1158/1078-0432. CCR-11-26961078-0432CCR-11-2696 [pii]. PMID: 22421194; PubMed Central PMCID: PMC3533370.
35. Board RE, Thelwell NJ, Ravetto P.F., Little S., Ranson M, Dive C, et al Multiplexed assays for detection of mutations in PIK3CA. Clin Chem. 2008; 54(4):757-60. Epub 2008/04/01. doi:10.1373/clinchem.2007.098376clinchem. 2007.098376 [pii]. PMID: 18375489.
36. Board RE, Wardley AM, Dixon J.M., Armstrong AC, Howell S, Renshaw L, et al Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat. 2010; 120 (2):461-7. Epub 2010/01/29. doi:10.1007/s10549-010-0747-9 PMID: 20107891.
37. Ruijter JM, Pfaffl MW, Zhao S, Spiess A.N., Boggy G., Blom J, et al. Evaluation of qPCR curve analysis methods for reliable biomarker discovery: bias, resolution, precision, and implications. Methods:. 2013; 59(1):32-46. doi:10.1016/j.ymeth.2012.08.011 PMID: 22975077.
38. Giard DJ, Aaronson SA, Todaro G.J., Arnstein P., Kersey JH, Dosik H, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973; 51 (5):1417-23. PMID: 4357758.
39. Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci USA. 1976; 73(9):3278-82. PMID: 1067619; PubMed Central PMCID: PMC431008.
40. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst. 1977; 59(1):221-6. PMID: 327080.
41. Johnson JP, Demmer-Dieckmann M, Meo T, Hadam MR, Riethmuller G. Surface antigens of human melanoma cells defined by monoclonal antibodies. I. Biochemical characterization of two antigens found on cell lines and fresh tumors of diverse tissue origin. Eur J Immunol. 1981; 11(10):825-31. doi:10.1002/eji.1830111015 PMID: 6895502.
42. Haluska FG, Tsao H, Wu H., Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res. 2006; 12(7 Pt 2):2301s-7s. Epub 2006/04/13. doi:12/7/2301s [pii] doi: 10.1158/1078-0432.CCR-05-2518 PMID: 16609049.
43. Hoeller C, Thallinger C, Pratscher B., Bister MD, Schicher N, Loewe R, et al The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J Invest Dermatol. 2005; 124(6):1293-9. Epub 2005/06/16. JID23685 [pii] doi: 10.1111/j.0022-202X.2005.23685.x PMID: 15955106.
44. Werzowa J, Cejka D, Fuereder T, Dekrout B, Thallinger C, Pehamberger H, et al. Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002. Br J Dermatol. 2009; 160(5):955-64. Epub 2009/01/06. doi: BJD8991 [pii] doi: 10.1111/j.1365-2133.2008.08991.x PMID: 19120326.
45. Bosserhoff AK, Hauschild A, Hein R., Schadendorf D, Stockfleth E, Bogenrieder T, et al. Elevated MIA serum levels are of relevance for management of metastasized malignant melanomas: results of a German multicenter study. J Invest Dermatol. 2000; 114(2):395-6. Epub 2000/03/18. doi:10.1046/j.1523-1747.2000.00889.x PMID: 10722327.
46. Burgstaller JP, Schinogl P, Dinnyes A, Muller M, Steinborn R. Mitochondrial DNAheteroplasmy in ovine fetuses and sheep cloned by somatic cell nuclear transfer. BMC DevBiol. 2007; 7:141. Epub 2007/12/25. doi:1471-213X-7-141 [pii] doi: 10.1186/1471-213X-7-141 PMID: 18154666; PubMed Central PMCID: PMC2323970.
47. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003; 31(13):3406-15. Epub 2003/06/26. PMID: 12824337; PubMed Central PMCID: PMC169194.
48. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, et al. BLAST+: architecture and applications. BMC Bioinformatics. 2009; 10:421. Epub 2009/12/17. doi:10.1186/1471-2105-10-4211471-2105-10-421 [pii]. PMID: 20003500; PubMed Central PMCID: PMC2803857.
49. Rossmanith P, Wagner M. A novel poisson distribution-based approach fortesting boundaries of realtime PCR assays for food pathogen quantification. J Food Prot. 2011; 74(9):1404-12. doi:10.4315/0362-028X.JFP-10-458 PMID: 21902908.
50. Kuhne BS, Oschmann P. Quantitative real-time RT-PCR using hybridization probes and imported standard curves for cytokine gene expression analysis. BioTechniques. 2002; 33(5):1078, 80-2, 84 passim. Epub 2002/11/27. PMID: 12449386.
51. Hall RD, Kudchadkar RR BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. Cancer Control. 2014; 21(3):221-30. Epub 2014/06/24. PMID: 24955706.
52. Boursault L, Haddad V, Vergier B., Cappellen D, Verdon S, Bellocq J.P., et al. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoSOne. 2013; 8(8):e70826. doi:10.1371/journal.pone.0070826 PMID: 23976959; PubMed Central PMCID: PMC3748080.
53. Menzies AM, Lum T, Wilmott JS, Hyman J, Kefford RF, Thompson JF, et al. Intrapatient homogeneity of BRAFV600E expression in melanoma. Am J Surg Pathol. 2014; 38(3):377-82. doi:10.1097/PAS.0000000000000136 PMID: 24335665.
54. Nordgard O, Oltedal S, Janssen E.A., Gilje B., Korner H, Tjensvoll K, et al Comparison of a PNA clamp PCR and an ARMS/Scorpion PCR assay for the detection of K-ras mutations. Diagn Mol Pathol. 2012; 21(1):9-13. doi:10.1097/PDM.0b013e31821e59dc PMID: 22306670.
55. Klein D. Quantification using real-time PCR technology: applications and limitations. Trends Mol Med. 2002; 8(6):257-60. PMID: 12067606.
56. Diehl F, Diaz LA Jr. Digital quantification of mutant DNA in cancer patients. CurrOpin Oncol. 2007; 19 (1):36-42. doi:10.1097/CCO.0b013e328011a8e7 PMID: 17133110.
57. Pekin D, Skhiri Y, Baret J.C., Le Corre D, Mazutis L, Salem C.B., et al. Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. Lab Chip. 2011; 11(13):2156-66. doi:10.1039/c11c20128j PMID: 21594292.
58. Hwang VJ, Maar D, Regan J., Angkustsiri K, Simon TJ, Tassone F. Mapping the deletion endpoints in individuals with 22q11.2 deletion syndrome by droplet digital PCR. BMC Med Genet. 2014; 15:106. doi:10.1186/s12881-014-0106-5 PMID: 25312060; PubMed Central PMCID: PMCPMC4258952.
59. Spellman PT, Gray JW Detecting cancer by monitoring circulating tumor DNA. Nat Med. 2014; 20 (5):474-5. doi:10.1038/nm.3564 PMID: 24804754.
60. Handsaker RE, Van Doren V, Berman JR, Genovese G, Kashin S., Boettger LM, et al. Large multiallelic copy number variations in humans. Nat Genet. 2015; 47(3):296-303. doi:10.1038/ng.3200 PMID: 25621458; PubMed Central PMCID: PMCPMC4405206.
61. Berg M, Nordgaard O, Korner H, Oltedal S, Smaaland R, Soreide JA, et al. Molecular subtypes in stage II-III colon cancer defined by genomic instability: early recurrence-risk associated with a high copy-number variation and loss of RUNX3 and CDKN2A. PLoSOne. 2015; 10(4):e0122391. doi:10.1371/journal.pone.0122391 PMID: 25879218; PubMed Central PMCID: PMCPMC4399912.